Herrera CÁ, Mendoza SAB, Velázquez TD

Idioma: Español
Referencias bibliográficas: 50
Paginas: 193-204
Archivo PDF: 115.45 Kb.

RESUMEN

Las enfermedades cardiovasculares son la primera causa de mortalidad en los países desarrollados, en Estados Unidos de Norteamérica (EUA) aproximadamente 838 mil egresos se produjeron en el 2005 de pacientes con diagnóstico de infarto agudo al miocardio (IAM), de los cuales entre el 29-47% correspondieron a un síndrome coronario agudo con elevación del ST (SICAEST). Recientemente se ha observado un gran interés en desarrollar estrategias para reducir el tiempo puerta-balón, para de esta forma aumentar el número de pacientes que sean elegibles para terapia de reperfusión. Lo que nos motiva a presentar esta revisión de 50 artículos. Un tratamiento oportuno y rápido incrementa la probabilidad de sobrevida para aquellos pacientes con IAM y elevación del ST, es por esto que contar con infraestructura adecuada y personal hospitalario capacitado puede influir en el pronóstico de estos pacientes al desarrollar e implementar sistemas y procesos que minimicen los intervalos de llegada de los pacientes y su tratamiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rosamond W, Flegal K, Furie K et al. Heart Disease and stroke statistics: 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.

2. Virmani R, Burke AP, Farb A. Plaque Rupture and Plaque erosion. Thromb Haemost 1999: 82(Suppl 1):1-3.

3. Morrow DA, Antman EM, Charlesworth A et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102 (17): 2031-2037.

4. Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–42.

5. Gregg W, Stone MD. Angioplasty strategies in ST-Segment-elevation myocardial infarction. Part I primary percutaneous coronary intervention. Circulation 2008; 118: 538-551.

6. Ting HH, Bradley EH, Wang Y et al. Delay in presentation and reperfusion therapy in ST-Elevation myocardial infarction. The American Journal of Medicine 2008; 121: 316-323.

7. Bradley EH, Herrin J, Wang Y et al. Strategies for reduction the door-to-ballon time in acute myocardial infarction. N Engl J Med 2006; 355: 2308-2320.

8. McNamara RL, Herrin J, Bradley EH et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction 1999-2002. J Am Coll Cardiol 2006; 47: 45-51.

9. Stone GW. Angioplasty strategies in ST- Segment-elevation myocardial infarction: Part II intervention after fobrinolytic therapy, integrated treatment recommendations, and future directions. Circulation 2008; 118: 552-566.

10. Sgarbossa EB, Pinsky SL, Barbagelata A et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in presence of left bundle branch block. N Engl J Med 1996; 334: 481-487.

11. Sehoming A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatet and anticoagulant therapy after placement of coronary stents. N Engl J Med 1996; 334: 1084-1089.

12. Stone GW, Grines CL. Primary angioplasty in acute myocardial infarction: comparative analysis with thrombolytic therapy. Interventional Cardiovascular Medicine: Principles and Practice. 2nd ed. Philadelphia. Pa: Churchill Livingston; 2001: 227-300.

13. Stone GW, Dixon SR. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol. 2007: 100: 1370-1375.

14. Nallamothu BR, Antman EM. Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment? Am J Cardiol 2004; 94: 772-774.

15. Boersma E, for the primary coronary angioplasty vs thrombolysis group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27: 779-788.

16. Stenestrand U, LIndback J, Wallentin L, for the RIKS-HIA registry. Long term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006; 296: 1749-1756.

17. Jollis JG, Peterson ED, Delon ER et al. The relation between the volume od coronary angioplasty precedures at hospitals treating Medicare beneficiaries and short term mortality. N Engl J Med 1994; 331: 1625-1629.

18. Fibrinolytic therapy triallist (FTT), Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994; 334: 311-322.

19. Newby LK, Rutsch WR, Califf RM et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy: GUSTO-I investigators. J Am Coll Cardiol 1996; 27: 1646-1655.

20. Schomig A, Mehili J. A mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005; 293: 2865-2872.

21. Hochman JS, Lamas GA. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355: 2395-2407.

22. Ellis SG, Da Silva ER, Spaulding CM et al. Review of immediate angioplasty after fibrinolytic therapy for AMI. Insights from the RESCUE 1 11, and other contemporary clinical experiences. AM Heart J 2000; 139: 1046-1053.

23. Hamdan NMD. Angioplastia primaria (ACTP) y angioplastia de rescate (ATCR). Medicrit 2004; 1(4): 141-145.

24. Stone GW, Grines CL. Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary coronary angioplasty. J Am Coll Cardiol 1955; 26: 66-72.

25. Stone GW, Moses JW. Safety and efficacy of sirolimus- and paclitaxel-elutin coronary stents. N Engl J Med 2007; 356-990-1008.

26. Paseri V, Patti G. Meta-analysis of clinical trials on ise of drug-eluting stents door treatment of acute myocardial infarction. Am Heart J 2007; 153: 749-754

27. Tierala L. HAAMU-STENT trial. Presented at transcather cardiovascular therapeutics meeting (TCT 2006): 2006; Washington, DC. Available at: www.cardiosource.com.

28. Applegate RJ. Incidence of coronary stent thrombosis based on academic research consortium definitions. Am J Cardiol 2008; 102(6): 683-688.

29. Yan BP. Rates of stent thrombosis in bare-metal versus drug-eluting stents: from a large Australian multicenter registry. Am J Cardiol 2008; 101(12): 1716-1722.

30. Stefan KJ, Ulf Stenestrand et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in sweden. NEJM 2009; 360: 1933-1945.

31. Wijeysundera HC. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: a meta-analysis of contemporary randomized controlled trials. Am Heart J 2008; 156(3): 564-572, 572.e1-2.

32. Sabatine MS, Cannon CP. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-1232.

33. De luca G, Suryapranata H. Abciximab as adjunctive therapy to reperfusion in acute St-segment elevation myocardial infarction: a meta-analysis of randomized trails. JAMA 2005; 293: 1759-1765.

34. Lincoff AM, Bittle JA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 2003; 289: 853-863.

35. Cannon CP, Gibson MC et al. Relationship of symptom-onset –to-baloon time and door-to balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283(22): 2941-2947.

36. Jeffe A. Elevations in cardiac troponin measurements: false false-positives: the real truth. Cardiovasc Toxicol 2001; 1: 87-92.

37. Eggers K, Oldgren J, Nordenskjold A et al. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004; 148: 574-581.

38. Hamm GC, Goldman BU, Heeschen C et al. emergency room triage of patients with chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337: 1648-1653.

39. Iwanga Y, Nishi I, Furuichi S et al. B-type natriurétic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. J Am Coll Cardiol 2006; 47: 742-748.

40. Morrow D, De Lemos J, Blazing M et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005; 294: 2866-2871.

41. Hansson G, Libby P. The immune response in atherosclerosis: a doble-edge sword. Nat Rev Immunol 2006; 6: 508-519.

42. Myers G, Rifai N, Tracy R et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the laboratory science discussion group. Circulation 2004; 110: 545-549.

43. Lin JC, Apple FS, Murakami MM et al. Rates of positive cardiac troponin I and creatine kinasa MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem 2004; 50: 333-338.

44. Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. Med Clin N Am 2007; 91: 657-681.

45. Lund J, Qin Q, Ilva T et al. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924-1926.

46. Lenderink T, Heeschesn C, Fichtlscherer S et al. Elevated placental growth factor levels are associated with adverse outcome at four years follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 307-311.

47. Ohman E, Armstrong P, Christenson R et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333-1341.

48. Barba EJR. Síndrome coronario agudo: Marcadores de lesión miocárdica. Rev Mex Patol Clin 2007; 54(3): 116-135.

49. De Luca G, Suryapranata H, Zijlstra F et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. JACC 2003; 42(2): 991-997.

50. Bueno H, Badaji A et al. Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del estado de los síndromes coronarios agudos en un registro temporal español).